Switch from EFV-TDF-FTC to RPV-TDF-FTC

GS-264-0111

Switch from **EFV**-TDF-FTC to **RPV**-TDF-FTC
GS-264-0111: Study Design

Study Design: GS-264-0111 Study

- **Background**: Open-label, phase 2b study evaluating the efficacy and safety of switching from EFV-TDF-FTC to RPV-TDF-FTC in virologically suppressed patients with HIV-1
- **Inclusion Criteria (n = 49)**
  - Age ≥18 years
  - On EFV-TDF-FTC for ≥3 months
  - Experiencing efavirenz intolerance
  - HIV RNA <50 copies/mL for ≥8 weeks
  - No resistance to study drugs
  - No proton pump inhibitor use
  - CrCl ≥50 mL/min
- **Switch Arm**
  - Rilpivirine-tenofovir DF-emtricitabine



Source: Mills AM, et al. HIV Clin Trials. 2013;14:216-23.

Switch from **EFV**-TDF-FTC to **RPV**-TDF-FTC
GS-264-0111: Result

Virologic Outcomes at Weeks 12, 24, and 48



Source: Mills AM, et al. HIV Clin Trials. 2013;14:216-23.

National HIV Curriculum

Switch from **EFV**-TDF-FTC to **RPV**-TDF-FTC

GS-264-0111: Result

Week 24: Change in Plasma Lipids from Baseline



Lipid Changes in Patients Switched to RPV-TDF-FTC

Source: Mills AM, et al. HIV Clin Trials. 2013;14:216-23.

Switch from **EFV**-TDF-FTC to **RPV**-TDF-FTC
GS-264-0111: Conclusions

Conclusions: “Switching from EFV/FTC/TDF to RPV/FTC/ TDF was a safe, efficacious option for virologically suppressed HIV-infected patients with efavirenz intolerance wishing to remain on an single tablet regimen.”

Source: Mills AM, et al. HIV Clin Trials. 2013;14:216-23.

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

National HIV Curriculum

AETC AIDS Education & Training Center Program